Provided by Tiger Trade Technology Pte. Ltd.

Assertio Holdings, Inc.

11.84
-0.2200-1.82%
Post-market: 12.100.2600+2.20%18:00 EST
Volume:22.93K
Turnover:273.94K
Market Cap:75.97M
PE:-2.62
High:12.19
Open:12.00
Low:11.71
Close:12.06
52wk High:15.15
52wk Low:7.71
Shares:6.42M
Float Shares:5.68M
Volume Ratio:0.67
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5263
EPS(LYR):-3.4500
ROE:-24.48%
ROA:-4.17%
PB:0.72
PE(LYR):-3.43

Loading ...

Assertio Holdings, Inc. Q3 Income From Operations USD 11.478 Million

THOMSON REUTERS
·
Nov 11, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025

Assertio Holdings Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07, 2025

Assertio Therapeutics Announces New CEO Appointment

TIPRANKS
·
Oct 31, 2025

BRIEF-Assertio Announces Leadership Transition

Reuters
·
Oct 28, 2025

Assertio Holdings Inc - Brendan P. O'grady to Depart Assertio

THOMSON REUTERS
·
Oct 28, 2025

Press Release: Assertio Announces Leadership Transition

Dow Jones
·
Oct 28, 2025

Assertio Therapeutics Amends ROLVEDON Supply Agreement

TIPRANKS
·
Oct 11, 2025

Assertio Holdings Inc - Spectrum and Hanmi Amend Supply Agreement - SEC Filing

THOMSON REUTERS
·
Oct 11, 2025

Assertio Holdings Inc - Rolvedon Price Reduced by Mid-Single Digit Percentage - SEC Filing

THOMSON REUTERS
·
Oct 11, 2025

Assertio Holdings Subsidiary Spectrum Pharmaceuticals Amends Supply Agreement with Hanmi Pharmaceutical for Rolvedon Drug Substance

Reuters
·
Oct 11, 2025

Assertio Therapeutics’ Growth Potential Driven by Sympazan and Stable Revenue Streams

TIPRANKS
·
Sep 16, 2025

Buy Rating Affirmed for Assertio Therapeutics Amid Positive Sympazan Study and Strong Financial Outlook

TIPRANKS
·
Sep 16, 2025

Assertio presents new data from study of SYMPAZAN Oral Film

TIPRANKS
·
Sep 15, 2025

BRIEF-FDA Says Assertio Specialty Pharmaceuticals Discontinues Manufacturing Of Otrexup, Injection

Reuters
·
Aug 29, 2025

FDA: Assertio Specialty Pharmaceuticals Discontinues Manufacturing of Otrexup, Injection- Website

THOMSON REUTERS
·
Aug 29, 2025

Assertio Holdings Q2 Adj. EPS $0.02 Beats $(0.08) Estimate, Sales $29.22M Beat $27.86M Estimate

Benzinga
·
Aug 12, 2025

BRIEF-Assertio Holdings, Inc. Q2 Adjusted EPS USD 0.02 Vs. IBES Estimate USD -0.08

Reuters
·
Aug 12, 2025

Assertio Holdings, Inc. Q2 EPS USD -0.17

THOMSON REUTERS
·
Aug 12, 2025